Comparing two drug combinations for untreated double-hit lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests two different drug combinations to see which is better for people with a type of lymphoma that has certain genetic markers. It aims to improve outcomes for patients who have not received treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma that is CD20 positive.
- Your cancer cells must show high levels of two proteins called MYC and BCL2.
- You must be in reasonably good health (able to care for yourself).
- You must not have had previous chemotherapy or other systemic treatment for your lymphoma.
- You must not have any other current or past cancer (except for certain skin or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new sequence of two chemotherapy regimens (RLC followed by CR-CHOP) for elderly patients with a fast-growing DLBCL called double expressor lymphoma. The goal is to see if this approach is safe and effective for people who may not tolerate standard treatments.
This trial tests a new combination of drugs for a type of lymphoma that is harder to treat. The goal is to improve outcomes for patients aged 65 and older who have this specific genetic feature.
This trial compares two treatments for a certain type of aggressive lymphoma: the standard R-CHOP chemotherapy plus a study drug called tucidinostat (which may help fight cancer cells). The aim is to see if adding this drug helps patients with the double-expressor subtype do better.
This trial compares two different combinations of chemotherapy drugs for people whose large B-cell lymphoma has come back more than a year after treatment. The goal is to see which regimen is more effective and safer.
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
This study tests a new treatment combination (CD-RCHOP, likely a form of chemotherapy with an antibody) for people with a high-risk type of diffuse large B-cell lymphoma that has certain genetic changes (TP53 mutation and 17p deletion). It aims to see if this approach is safe and effective for this specific group.
Hear when a new Double Expressor Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.